Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Cancer Stem-Like Cells in Glioblastoma

Mathilde Cheray  1 , Gaëlle Bégaud  2   3 , Elise Deluche  4 , Alexandre Nivet  5 , Serge Battu  2   3 , Fabrice Lalloué  2 , Mireille Verdier  2 , Barbara Bessette  2
Steven De Vleeschouwer  1
, editors.
In: Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017 Sep 27. Chapter 4.
Affiliations
Review

Cancer Stem-Like Cells in Glioblastoma

Mathilde Cheray et al.

Excerpt

Glioblastoma is currently described as the worst brain tumor because of its aggressiveness and poor prognosis. Chemotherapy and irradiation are not curative, and the average survival for patients with glioblastoma is around 15 months. The cellular heterogeneity and infiltrative capability of glioblastoma make complete surgical resection almost impossible. Moreover, the presence of cancer stem-like cells in this tumor leads to therapeutic resistance and tumor recurrence after surgery. Numerous studies have explored the physiology of these cancer stem cells, and attempts have been made to develop devices aimed at isolating this rare population of cells. This chapter describes the complexity of cancer stem cells in glioblastoma. Their role in autophagy, gene regulation by epigenetic modifications, and the challenges in isolating these cells are addressed. This knowledge may pave the way for a better understanding of cancer stem cells in glioblastoma, and the potential development of new therapeutic strategies for this deadly disease.

PubMed Disclaimer

References

    1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987–96. doi: 10.1056/NEJMoa043330. - DOI - PubMed
    1. Erdem-Eraslan L, van den Bent MJ, Hoogstrate Y, Naz-Khan H, Stubbs A, van der Spek P, et al. Identification of patients with recurrent glioblastoma who may benefit from combined bevacizumab and CCNU therapy: A report from the BELOB trial. Cancer Res. 2016 Feb 01;76(3):525–34. doi: 10.1158/0008-5472.CAN-15-0776. - DOI - PubMed
    1. Schafer N, Gielen GH, Kebir S, Wieland A, Till A, Mack F, et al. Phase I trial of dovitinib (TKI258) in recurrent glioblastoma. J Cancer Res Clin Oncol. 2016;142(7):1581–9. doi: 10.1007/s00432-016-2161-0. - DOI - PubMed
    1. Tang X, Li Q, Zhu Y, Zheng D, Dai J, Ni W, et al. The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy. Am J Transl Res. 2015;7(3):460–73. - PMC - PubMed
    1. Heiland DH, Haaker G, Delev D, Mercas B, Masalha W, Heynckes S, et al. Comprehensive analysis of PD-L1 expression in glioblastoma multiforme. Oncotarget. 2017 Jun 27;8(26):42214–25. doi: 10.18632/oncotarget.15031. - DOI - PMC - PubMed